2021 has been a significant year for Anatara Lifesciences Limited (ASX:ANR), as we made steps towards progressing our human health products towards clinical trials, successfully completed animal health studies and progressed licensing discussions.
Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal health in humans and animals, invites shareholders to attend a virtual group briefing with Chief Executive Officer, Steven Lydeamore, on Thursday 9 September 2021 at 11:00am AEST.
Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals, is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr. Steven Lydeamore, will present today to investors.
I am pleased to provide you with a detailed update on BTC Health Limited's (ASX:BTC) investments, along with an operational update of BTC's wholly owned investee companies.
Bluechiip Limited's (ASX:BCT) (FRA:1BL) unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels.
Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to announce the launch of its IBS-D Clinical Trial recruitment website.
The primary objective for BTC Speciality Health is to increase market share through organic growth. New products will continue to be sourced by BioImpact and will enable BTC Speciality Health to expand its product range within pain management and critical care.
